Pharmacotherapy considerations with finerenone in the treatment of chronic kidney disease associated with type 2 diabetes
Pharmacotherapy considerations with finerenone in the treatment of chronic kidney disease associated with type 2 diabetes is a paper indexed in ScholarIQ from OpenAlex.
How many citations does Pharmacotherapy considerations with finerenone in the treatment of chronic kidney disease associated with type 2 diabetes have?
Pharmacotherapy considerations with finerenone in the treatment of chronic kidney disease associated with type 2 diabetes has 19 citations in the OpenAlex counts ScholarIQ stores.
When was Pharmacotherapy considerations with finerenone in the treatment of chronic kidney disease associated with type 2 diabetes published?
Pharmacotherapy considerations with finerenone in the treatment of chronic kidney disease associated with type 2 diabetes has 2023 year in the ScholarIQ index.
What is the open-access status of Pharmacotherapy considerations with finerenone in the treatment of chronic kidney disease associated with type 2 diabetes?
Pharmacotherapy considerations with finerenone in the treatment of chronic kidney disease associated with type 2 diabetes has hybrid oa status in the ScholarIQ index.
What is the DOI of Pharmacotherapy considerations with finerenone in the treatment of chronic kidney disease associated with type 2 diabetes?
The DOI for Pharmacotherapy considerations with finerenone in the treatment of chronic kidney disease associated with type 2 diabetes is on the source record.
What is the PMID of Pharmacotherapy considerations with finerenone in the treatment of chronic kidney disease associated with type 2 diabetes?
The PMID for Pharmacotherapy considerations with finerenone in the treatment of chronic kidney disease associated with type 2 diabetes is on the source record.
What is the OpenAlex record for Pharmacotherapy considerations with finerenone in the treatment of chronic kidney disease associated with type 2 diabetes?
The OpenAlex for Pharmacotherapy considerations with finerenone in the treatment of chronic kidney disease associated with type 2 diabetes is on the source record.